India’s drug regulatory system is under the lens again after the World Health Organization’s (WHO) latest medical product alert on two substandard cough syrups manufactured in the country.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: 2seventy, Affamed, Akeso, Astellas, Catalyst, Concert, Cytomx, Eisai, Eli Lilly, F-star, Genkore, Invox, JW, KSQ, Medigene, Nogra, Novartis, Ono, Recce, Repare, Sab, Sandoz, Senti, Sino, Summit, Sun, Torii.
Biopharmas in Asia-Pacific raising money in public or private financings: Asahi Kasei, Biolife Solution, Bristol Myers Squibb, Charles River, Harbour Biomed, HBM Alpha, Iaso, Ivexsol, Kazia.
While it made a sturdy effort as biopharma companies opted for licensing deals over M&As in 2022, the year did not surpass 2021 in deal values, falling about 3.5% short. Lackluster M&A values dropped to their lowest levels in five years and were down by 35.6% compared with 2021.
Now in its 10th year, Clarivate’s newly released Drugs to Watch 2023 report primarily features treatments targeted to a particular biomarker, signaling the advance and increasing potential of personalized medicines. The 15 drugs on the list are anticipated to either register sales of more than $1 billion by 2027 or be clinical game changers. Nine are predicted to hit $1 billion annual sales each in China by 2030.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Adagene, Arrowhead, Hightide, Jacobio, Sorrento, Takeda.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Biogen, Biontech, Dizal, Eisai, H. Lundbeck, Otsuka, Pfizer, SK, Takeda.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Ajinomoto, Alvotech, Exelixis, Fuji.
RSS
